Peptide therapy TikTok claims: what the science actually supports

What did @christian.fleenor actually say?

Christian laid out a beginner protocol for what he calls "reti" — retatrutide, a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 trials. He recommends starting at "0.5 milligrams for one to two weeks," titrating up every two weeks if weight isn't moving, dialing in protein-heavy nutrition, and doing cardio. He also says side effects like "diarrhea, stomach cramps, GI issues" mean your dose is too high, and that you should drop back 0.5 mg and hold there. He closes by offering a personalized DM protocol.

That's a lot of specific clinical-sounding guidance for a compound that has no FDA approval, no established prescribing label, and is currently only available through compounding pharmacies or gray-market research chemical suppliers. That context is completely absent from his video.

Does the science back this up?

Some of it does, loosely. Retatrutide's Phase 2 trial data (Jastreboff et al., 2023, NEJM) used a slow titration schedule starting at low doses, and GI side effects were the primary driver of discontinuation. So the general concept of starting low and titrating based on tolerance isn't invented. But the specific doses and timelines he names don't come from published clinical data — they come from compounding community forums.

The trial used subcutaneous weekly injections at escalating doses from 0.5 mg up to 12 mg, with structured titration intervals of 4 weeks, not 1-2 as he suggests. The 24-week results showed up to 17.5% body weight reduction at the highest dose. Importantly, the trial population was controlled, monitored by physicians, and excluded people with numerous comorbidities. Generalizing from that to "just DM me for your protocol" is a significant leap.

What did they get wrong (or right)?

Credit where it's due: the nutrition advice is solid. Prioritizing protein to preserve lean mass during GLP-1-class drug use is backed by real evidence. Seifarth et al. (2023, Diabetes, Obesity and Metabolism) found that muscle mass loss is a meaningful concern with rapid weight loss from GLP-1 receptor agonists, and resistance training plus adequate protein intake are the primary mitigation strategies. He's right that "you're gonna lose muscle" if you undereating protein, and that's not a minor point.

Where he goes wrong: his claim that "if you're experiencing side effects, your dosage is way too high" is an oversimplification. GI side effects during titration are common even at appropriate doses, especially in early weeks. They often resolve without dose reduction. The clinical approach is to hold the dose, not reflexively drop it. His binary framing — side effects mean too high, no side effects means keep going — could lead someone to under-dose a medication that only works above a threshold, or to ignore symptoms that warrant medical attention, not just a dose tweak.

What should you actually know?

Retatrutide is not approved by the FDA. It is not legally available as a finished drug product. What's circulating is either from compounding pharmacies operating under specific legal frameworks or from research chemical suppliers with no quality controls. Purity, sterility, and actual dose concentration are not guaranteed in either case.

The dosing ranges circulating online — including what Christian describes — are largely extrapolated from the Jastreboff trial or from anecdotal community experience. There is no established safe starting dose for general public use because this drug has never been approved for general public use. Titration schedules that work for a monitored clinical trial participant may not work for someone self-administering without bloodwork, without a baseline metabolic panel, and without a physician watching for pancreatitis, thyroid changes, or cardiovascular effects.

If you're interested in GLP-1-class therapies for weight management, the appropriate path is through a licensed provider who can assess your full health picture, not a TikTok DM offering a "protocol."